Literature DB >> 33778723

Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.

Chong Hyun Suh1, Ho Sung Kim1, Ji Eun Park1, Seung Chai Jung1, Choong Gon Choi1, Dong-Cheol Woo1, Ho Beom Lee1, Sang Joon Kim1.   

Abstract

Purpose: To compare the ability of 2-hydroxyglutarate (2HG)-to-lipid and lactate (2HG/[lipid + lactate]) ratio with the ability of 2HG concentration alone to predict the isocitrate dehydrogenase (IDH) mutation status in patients with glioma. Materials and
Methods: In this retrospective study, consecutive patients with histopathologically proven glioma were enrolled between July 2016 and February 2019. A total of 79 patients were enrolled (mean age, 44 years; 49 men). The 2HG concentration and other MR spectroscopic parameters were measured by single-voxel point-resolved spectroscopy before surgery. The diagnostic performance of the 2HG concentration and 2HG/(lipid + lactate) ratio were calculated. Internal validation was assessed by the bootstrap approach with 1000 bootstrap resamples. Differences in the predictive accuracy of 2HG/(lipid + lactate) ratio and 2HG concentration were determined by calculating the integrated discrimination improvement. The diagnostic accuracy (sensitivity, specificity, and area under the receiver operating characteristic curve [AUC]) of these measures was also compared separately in patients with glioblastomas and patients with lower-grade gliomas.
Results: Of the 79 enrolled patients, 28 had IDH mutations and 51 had wild-type IDH. The sensitivity, specificity, and AUC of 2HG concentration for predicting IDH-mutant gliomas were 89% (25 of 28), 67% (34 of 51), and 0.80 (95% confidence interval [CI]: 0.70, 0.88; C statistic, 0.80), respectively. The sensitivity, specificity, and AUC of the 2HG/(lipid + lactate) ratio for predicting IDH-mutant gliomas were 79% (22 of 28), 92% (47 of 51), and 0.90 (95% CI: 0.81, 0.96; C statistics, 0.90), respectively. The optimal cutoff value for the 2HG/(lipid + lactate) ratio was 0.63. The 2HG/(lipid + lactate) ratio was significantly better for predicting IDH mutation status than the 2HG concentration alone (P < .01). In glioblastoma, the 2HG/(lipid + lactate) ratio was also better for predicting IDH mutations than the 2HG concentration alone, with borderline significance (P = .052). In lower-grade glioma, the 2HG/(lipid + lactate) ratio and the 2HG concentration showed comparable diagnostic performance (P = .72).
Conclusion: The 2HG/(lipid + lactate) ratio is more accurate for predicting IDH mutation status in patients with glioma than the 2HG concentration alone.Keywords: Brain/Brain Stem, CNS, MR-Imaging, MR-Spectroscopy, Neoplasms-Primary, Neuro-Oncology© RSNA, 2020. 2020 by the Radiological Society of North America, Inc.

Entities:  

Year:  2020        PMID: 33778723      PMCID: PMC7983780          DOI: 10.1148/rycan.2020190083

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  25 in total

1.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

2.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T.

Authors:  Girolamo Crisi; Silvano Filice; Maria Michiara; Pellegrino Crafa; Silvia Lana
Journal:  J Comput Assist Tomogr       Date:  2018 May/Jun       Impact factor: 1.826

6.  Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.

Authors:  Ovidiu C Andronesi; Grace S Kim; Elizabeth Gerstner; Tracy Batchelor; Aria A Tzika; Valeria R Fantin; Matthew G Vander Heiden; A Gregory Sorensen
Journal:  Sci Transl Med       Date:  2012-01-11       Impact factor: 17.956

7.  Separation and quantification of lactate and lipid at 1.3 ppm by diffusion-weighted magnetic resonance spectroscopy.

Authors:  Anna M Wang; Gilberto K K Leung; Karrie M Y Kiang; Danny Chan; Peng Cao; Ed X Wu
Journal:  Magn Reson Med       Date:  2016-02-01       Impact factor: 4.668

8.  STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet; Herbert Y Kressel; Nader Rifai; Robert M Golub; Douglas G Altman; Lotty Hooft; Daniël A Korevaar; Jérémie F Cohen
Journal:  Radiology       Date:  2015-10-28       Impact factor: 11.105

9.  MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.

Authors:  Sotirios Bisdas; Grzegorz L Chadzynski; Christian Braun; Jens Schittenhelm; Marco Skardelly; Gisela E Hagberg; Thomas Ethofer; Rolf Pohmann; G Shajan; Jörn Engelmann; Ghazaleh Tabatabai; Ulf Ziemann; Ulrike Ernemann; Klaus Scheffler
Journal:  J Magn Reson Imaging       Date:  2016-03-11       Impact factor: 4.813

10.  Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.

Authors:  Uzay E Emir; Sarah J Larkin; Nick de Pennington; Natalie Voets; Puneet Plaha; Richard Stacey; Khalid Al-Qahtani; James Mccullagh; Christopher J Schofield; Stuart Clare; Peter Jezzard; Tom Cadoux-Hudson; Olaf Ansorge
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.